What's Going On With Iovance Biotherapeutics Stock On Friday?

Benzinga_recent_news03-07

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock is trading higher on Friday, with no news to justify the movement. Investors should note the company’s short interest sits as high as 39.6%, with a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617329016?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/06/3D-Illustration-Depicting-Cancer-Cells-I.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-07 02:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617329016","market":"us","top_or_hot":-1,"title":"What's Going On With Iovance Biotherapeutics Stock On Friday?","media":"Benzinga_recent_news","content":"<div>\n<p>Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock is trading higher on Friday, with no news to justify the movement.\nInvestors should note the company’s short interest sits as high as 39.6%, with a ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51105512/whats-going-on-with-iovance-biotherapeutics-stock-on-friday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Iovance Biotherapeutics Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Iovance Biotherapeutics Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-07 02:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51105512/whats-going-on-with-iovance-biotherapeutics-stock-on-friday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock is trading higher on Friday, with no news to justify the movement.\nInvestors should note the company’s short interest sits as high as 39.6%, with a ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51105512/whats-going-on-with-iovance-biotherapeutics-stock-on-friday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51105512/whats-going-on-with-iovance-biotherapeutics-stock-on-friday","article_id":"2617329016","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/06/3D-Illustration-Depicting-Cancer-Cells-I.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51105512/whats-going-on-with-iovance-biotherapeutics-stock-on-friday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2617329016","pubTimestamp":1772820360,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Iovance stock jumps despite no news as investors watch short interest and promising early data from its cancer therapy trial.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"周五Iovance Biotherapeutics股票走势如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock is trading higher on Friday, with no news to justify the movement.\nInvestors should note the company’s short interest sits as high as 39.6%, with a market capitalization of 1.66 billion, according to Benzinga Pro data.\nLast week, the company shared positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.\nThe trial, conducted by Memorial Sloan Kettering Cancer Center, reported a 50% confirmed objective response rate among the first six evaluable patients treated with lifileucel monotherapy.\nAdditionally, the company aims to explore lifileucel in other high-grade soft tissue sarcoma subtypes, further expanding its potential market reach.\nThe stock is currently trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, demonstrating strong momentum over the past year. Shares have increased 34.80% over the past 12 months and are currently positioned closer to their 52-week highs than lows.\nThe RSI is at 83.41, which is considered overbought territory, indicating that the stock may be due for a pullback.\nMeanwhile, MACD is at 0.4295, above its signal line at 0.2853, suggesting bullish momentum in the stock.\nThe combination of overbought RSI and bullish MACD indicates that while the stock is experiencing strong upward momentum, it may be approaching a point where profit-taking could occur.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $11.23. Recent analyst moves include:\nIOVA Price Action: Iovance Biotherapeutics shares were up 14.52% at $5.24 at the time of publication on Friday. The stock is trading at a new 52-week high, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617329016","isCrawlerRequest":true}